4.4 Article

Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome

期刊

CURRENT GENE THERAPY
卷 14, 期 6, 页码 422-428

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566523214666141001123828

关键词

Autoimmunity; cell therapy; Forkhead box P3; gene correction; Immune dysregulation Polyendocrinopathy Enteropathy X-linked syndrome; lentiviral vector; regulatory T cells

资金

  1. Italian Telethon foundation [TGT11A4]
  2. Italian Ministry of Health [RF-2009-1485896]
  3. Seventh Framework project of the European Community (Cell-PID)

向作者/读者索取更多资源

Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg cells results in the development of devastating autoimmune manifestations affecting multiple organs, eventually leading to premature death in infants, if not promptly treated by hematopoietic stem cell transplantation (HSCT). Novel gene therapy strategies can be developed for IPEX syndrome as more definitive cure than allogeneic HSCT. Here we describe the therapeutic approaches, alternative to HSCT, currently under development. We described that effector T cells can be converted in regulatory T cells by LV-mediated FOXP3-gene transfer in differentiated T lymphocytes. Despite FOXP3 mutations mainly affect a highly specific T cell subset, manipulation of stem cells could be required for long-term remission of the disease. Therefore, we believe that a more comprehensive strategy should aim at correcting FOXP3-mutated stem cells. Potentials and hurdles of both strategies will be highlighted here.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据